Records containing: Papilloma Viral Infection
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-03-30A Cluster Randomized Controlled Trial Testing Communication Strategies to Increase HPV Vaccination Intention: A Survey Experiment
-
CLINICAL_TRIALS study record update · 2024-10-26Reducing Urban Cervical Cancer Disparities Using a Tailored MHealth Intervention to Enhance Colposcopy Attendance
-
CLINICAL_TRIALS study record update · 2024-07-15Psycho-emotional Impact of Preoperative Counselling in Cervico-carcinoma Screening
-
CLINICAL_TRIALS study record update · 2024-02-07Evaluación de la Eficacia de la combinación de GLIZIGEN® solución Oral 1/día y Gel Vaginal 1/Noche Durante 2 Meses en Pacientes Con Neoplasia Intraepitelial Cervical de Grado 1 (LSIL/CIN-1) Causada Por el Virus Del Papiloma Humano de Alto Riesgo (VPH-AR).
-
CLINICAL_TRIALS study record update · 2022-09-10HPV Vaccination (Human Papilloma Virus), or How to Address Male Homosexuality in General Practice in Alsace?
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2022-03-02Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students
-
CLINICAL_TRIALS study record update · 2019-05-22Efficacy and Safety of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal. Phase II Clinical Trial
-
CLINICAL_TRIALS study record update · 2018-11-01A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men
-
CLINICAL_TRIALS study record update · 2018-10-29Immunogenicity of the HPV-6, 11, 16, 18 Vaccine Among Adolescent Girls Who Receive Vaccine Doses at Non-recommended Intervals and Factors Related to Non-adherence